Satsuma
is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of neurological disorders... Read moreSatsuma
is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of neurological disorders... Read more
News
May 02, 2025
The Business Journals: Greensboro/Winston-Salem/High Point
Satsuma: Durham firm wins approval for new migraine treatment
Nov 27, 2024
OINDPnews
Satsuma: FDA accepts Satsuma's resubmitted NDA for STS101 intranasal dry powder DHE for the treatment of migraine
Nov 01, 2024
The Business Journals
Satsuma: After setback, Durham pharma tries again for FDA approval
Jun 13, 2024
PR Newswire
Press Release: Satsuma : Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
Jan 19, 2024
Pharamceutical Technology
Satsuma: FDA declines to approve Satsuma's migraine treatment STS101
Jan 18, 2024
Endpoints News
Satsuma: Satsuma's nasal migraine candidate rejected by FDA over CMC issues
Jun 15, 2023
Benzinga
Satsuma: Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting
Jun 08, 2023
MarketScreener
Satsuma: Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K
Jun 08, 2023
The Business Journals: Raleigh/Durham
Satsuma: Japanese pharma acquires its Durham spin-out
May 19, 2023
Pharamceutical Technology
Satsuma: US FDA accepts Satsuma's 505(b)(2) NDA for STS101
Satsuma Competitors
1
2
3
4
5
6
7
8
9
10